Modeling glioblastoma complexity with organoids for personalized treatments

Authors：Pawlowski, Kristen D.; Duffy, Joseph T.; Babak, Maria, V^*; Balyasnikova, Irina, V^*

Source：Trends in Molecular Medicine, 2023, 29(4): 282-296.

DOI：10.1016/j.molmed.2023.01.002

• SALVAGE CHEMOTHERAPY
• ZIKA VIRUS
• ADJUVANT TEMOZOLOMIDE
• STEM-CELLS
• GLIOMA
• BEVACIZUMAB
• TUMORS
• GROWTH
• RADIOTHERAPY
• EXPRESSION

Glioblastoma (GBM) remains a fatal diagnosis despite the current standard of care of maximal surgical resection, radiation, and temozolomide (TMZ) therapy. One aspect that impedes drug development is the lack of an appropriate model representative of the complexity of patient tumors. Brain organoids derived from cell culture techniques provide a robust, easily manipulatable, and high-throughput model for GBM. In this review, we highlight recent progress in developing GBM organoids (GBOs) with a focus on generating the GBM micro -environment (i.e., stem cells, vasculature, and immune cells) recapitulating human disease. Finally, we also discuss the use of organoids as a screening tool in drug development for GBM.

• Institution
  西北大学